Your session is about to expire
← Back to Search
GLP-1 Receptor Agonist
LY3502970 for Type 2 Diabetes
Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
Awards & highlights
Summary
This trial is testing a new medication called LY3502970 to help people with type 2 diabetes control their blood sugar levels. It targets those who haven't had success with diet, exercise, or metformin. The study will last several months to see if LY3502970 is effective and safe.
Eligible Conditions
- Type 2 Diabetes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
Secondary study objectives
Change From Baseline in Body Weight
Change From Baseline in Fasting Serum Glucose
Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide
+3 moreSide effects data
From 2022 Phase 2 trial • 383 Patients • NCT0504871938%
Nausea
21%
Vomiting
16%
Diarrhoea
13%
Constipation
9%
Fatigue
9%
Covid-19
9%
Lipase increased
7%
Dyspepsia
7%
Gastrooesophageal reflux disease
5%
Palpitations
5%
Abdominal distension
5%
Decreased appetite
4%
Eructation
4%
Weight decreased
4%
Arthralgia
4%
Headache
4%
Urticaria
2%
Abdominal pain upper
2%
Upper respiratory tract infection
2%
Muscle spasms
2%
Dizziness
2%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 1
36 mg LY3502970 - 2
45 mg LY3502970 - 1
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide
Trial Design
9Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 45 mg LY3502970 - 2Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Group II: 45 mg LY3502970 - 1Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Group III: 36 mg LY3502970 - 2Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Group IV: 36 mg LY3502970 - 1Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Group V: 3 milligrams (mg) LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
Group VI: 24 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
Group VII: 12 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
Group VIII: 1.5 mg DulaglutideActive Control1 Intervention
Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
Group IX: PlaceboPlacebo Group1 Intervention
Participants received matching placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1270
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,651 Previous Clinical Trials
3,224,084 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,369 Previous Clinical Trials
421,011 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger